SARS-CoV-2 Seroprevalence Among Health Care Workers in Major Private and Public Hospitals With COVID-19 Patient's Referral in Tehran, Iran
Copyright © 2022 Darvishian, Sharafkhah, Mohammadi, Sadeghniiat-haghighi, Abdollahi, Jafary, Talaschian, Tabarsi, Baghai, Mardani, Shayanrad, Shafighian, Markarian, Roozafzai, Zamani, Alvand, Hariri, Sadeghi, Poustchi and Malekzadeh..
Estimating the prevalence of SARS-CoV-2 antibody seropositivity among health care workers (HCWs) is crucial. In this study, the seroprevalence of anti-SARS-CoV-2 antibodies among HCWs of five hospitals of Tehran, Iran with high COVID-19 patient's referrals from April to June, 2020, was assessed. In this cross-sectional study, HCWs from three public and two private hospitals, selected randomly as a pilot, were included. Participants were asked questions on their demographic characteristics, medical history, hospital role, and usage of personal protective equipment (PPE). Iran FDA-approved SARS-CoV-2 ELISA kits were used to detect IgG and IgM antibodies in blood samples. The seroprevalence was estimated on the basis of ELISA test results and adjusted for test performance. Among the 2,065 participants, 1,825 (88.4%) and 240 (11.6%) HCWs were recruited from public and private hospitals, respectively. A total of 340 HCWs were tested positive for SARS-CoV-2-specific IgG or IgM antibodies, and 17.9% of seropositive individuals were asymptomatic. The overall test performance-adjusted seroprevalence estimate among HCWs was 22.6 (95% CI: 20.2-25.1), and PPE usage was significantly higher among HCWs of public vs. private hospitals (66.5 vs. 20.0%). This study found that seroprevalence of SARS-CoV-2 among HCWs was higher in private hospitals (37.0%; 95% CI: 28.6-46.2) than public hospitals (20.7%; 95% CI: 18.2-23.3), and also highest among assistant nurses and nurses, and lowest among janitor or superintendent categories. The PPE usage was especially suboptimal among HCWs in private hospitals. Continued effort in access to adequate PPE and regular screening of hospital staff for detecting asymptomatic personnel, especially during the upcoming wave of infection, are warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Frontiers in public health - 10(2022) vom: 02., Seite 832003 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Darvishian, Maryam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 12.04.2022 Date Revised 20.07.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fpubh.2022.832003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339296852 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339296852 | ||
| 003 | DE-627 | ||
| 005 | 20231226002559.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fpubh.2022.832003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1130.xml |
| 035 | |a (DE-627)NLM339296852 | ||
| 035 | |a (NLM)35400056 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Darvishian, Maryam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 Seroprevalence Among Health Care Workers in Major Private and Public Hospitals With COVID-19 Patient's Referral in Tehran, Iran |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2022 | ||
| 500 | |a Date Revised 20.07.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Darvishian, Sharafkhah, Mohammadi, Sadeghniiat-haghighi, Abdollahi, Jafary, Talaschian, Tabarsi, Baghai, Mardani, Shayanrad, Shafighian, Markarian, Roozafzai, Zamani, Alvand, Hariri, Sadeghi, Poustchi and Malekzadeh. | ||
| 520 | |a Estimating the prevalence of SARS-CoV-2 antibody seropositivity among health care workers (HCWs) is crucial. In this study, the seroprevalence of anti-SARS-CoV-2 antibodies among HCWs of five hospitals of Tehran, Iran with high COVID-19 patient's referrals from April to June, 2020, was assessed. In this cross-sectional study, HCWs from three public and two private hospitals, selected randomly as a pilot, were included. Participants were asked questions on their demographic characteristics, medical history, hospital role, and usage of personal protective equipment (PPE). Iran FDA-approved SARS-CoV-2 ELISA kits were used to detect IgG and IgM antibodies in blood samples. The seroprevalence was estimated on the basis of ELISA test results and adjusted for test performance. Among the 2,065 participants, 1,825 (88.4%) and 240 (11.6%) HCWs were recruited from public and private hospitals, respectively. A total of 340 HCWs were tested positive for SARS-CoV-2-specific IgG or IgM antibodies, and 17.9% of seropositive individuals were asymptomatic. The overall test performance-adjusted seroprevalence estimate among HCWs was 22.6 (95% CI: 20.2-25.1), and PPE usage was significantly higher among HCWs of public vs. private hospitals (66.5 vs. 20.0%). This study found that seroprevalence of SARS-CoV-2 among HCWs was higher in private hospitals (37.0%; 95% CI: 28.6-46.2) than public hospitals (20.7%; 95% CI: 18.2-23.3), and also highest among assistant nurses and nurses, and lowest among janitor or superintendent categories. The PPE usage was especially suboptimal among HCWs in private hospitals. Continued effort in access to adequate PPE and regular screening of hospital staff for detecting asymptomatic personnel, especially during the upcoming wave of infection, are warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a health-care worker | |
| 650 | 4 | |a personal protective equipment | |
| 650 | 4 | |a seroprevalence | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 700 | 1 | |a Sharafkhah, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadi, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghniiat-Haghighi, Khosro |e verfasserin |4 aut | |
| 700 | 1 | |a Abdollahi, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Jafary, Mohamadreza |e verfasserin |4 aut | |
| 700 | 1 | |a Talaschian, Mona |e verfasserin |4 aut | |
| 700 | 1 | |a Tabarsi, Payam |e verfasserin |4 aut | |
| 700 | 1 | |a Baghai, Parvaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Mardani, Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Shayanrad, Amaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Shafighian, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Markarian, Melineh |e verfasserin |4 aut | |
| 700 | 1 | |a Roozafzai, Farzin |e verfasserin |4 aut | |
| 700 | 1 | |a Zamani, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Alvand, Saba |e verfasserin |4 aut | |
| 700 | 1 | |a Hariri, Sanam |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghi, Anahita |e verfasserin |4 aut | |
| 700 | 1 | |a Poustchi, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Malekzadeh, Reza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in public health |d 2013 |g 10(2022) vom: 02., Seite 832003 |w (DE-627)NLM23377548X |x 2296-2565 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g day:02 |g pages:832003 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fpubh.2022.832003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |b 02 |h 832003 | ||